Boehringer Ingelheim/Pfizer's once-daily Spiriva (tiotropium) may be more effective at reducing risk for exacerbations among people with moderate to severe COPD than GlaxoSmithKline's Serevent (salmeterol), shows a study published in the New England Journal of Medicine.
Both Spiriva and Serevent are long-acting bronchodilators, but they act via different mechanisms.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?